Login Register Cart 0
Generic placeholder image

Anti-Infective Agents

Editor-in-Chief

ISSN (Print): 2211-3525
ISSN (Online): 2211-3533

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Novel and Predictive QSAR Model and Molecular Docking: New Natural Sulfonamides of Potential Concern against SARS-Cov-2

Author(s): Nathalie Moussa* and Huda Mando

Volume 21, Issue 5, 2023

Published on: 24 August, 2023

Article ID: e170723218787 Pages: 11

DOI: 10.2174/2211352521666230717115823

Price: $65

Abstract

Background: Since the outbreak of the COVID-19 pandemic in 2019, the world has been racing to develop effective drugs for treating this deadly disease. Although there are now some vaccines that have somewhat alleviated global panic, the lack of approved drugs remains a persistent challenge. Consequently, there is a pressing need to discover new therapeutic molecules.

Methods: In this study, we explore the application of a quantitative structure−activity relationship (QSAR) model to predict the efficacy of 28 cyclic sulfonamide derivatives against SARS-CoV-2. The model was developed using multiple linear regression, and six molecular descriptors were identified as the most significant factors in determining the inhibitory activity. This proposed QSAR model holds the potential for aiding the virtual screening and drug design process in the development of new and more effective SARS-CoV-2 inhibitors. The model was also applied to seven natural products primary sulfonamides and sulfamates, demonstrating promising activity.

Results: The study results indicated that the atom count, as represented by the descriptor nCl, had the most significant impact on the inhibitory activity against SARS-CoV-2. The proposed model was validated using various statistical parameters, confirming its validity, robustness, and predictiveness, with a high correlation coefficient (R2) of 0.77 for the training group and 0.95 for the test group. Furthermore, we predicted the activity of seven natural compounds, and among them, Dealanylascamycin exhibited the highest predicted activity. Subsequently, Dealanylascamycin was docked to SARS-CoV- 2 and the results of the docking study further strengthened its potential as a promising candidate against COVID-19, suggesting that it should be considered for further optimization and validation.

Conclusion: Our findings demonstrate promising predicted inhibitory activity against SARS-CoV-2 for seven natural products, primary sulfonamides, and primary sulfamates.

Graphical Abstract

[1]
World Health Organization.. Novel Coronavirus 2019. Available From: https://www.who.int/emergencies/diseases/novel-coronavirus-2019
[2]
Seungtaek, K. New approaches in the screening and discovery of novel enzymes for industrial applications. J. Microbiol. Biotechnol., 2022, 32(1), 1-5.
[http://dx.doi.org/10.4014/jmb.2110.10029] [PMID: 34866128]
[3]
Centers for Disease Control and Prevention Interim Clinical Considerations for COVID-19 Treatment in Outpatients. 2019. Available From: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/outpatient-treatment-overview.html
[4]
Pandey, A.; Nikam, A.N.; Shreya, A.B.; Mutalik, S.P.; Gopalan, D.; Kulkarni, S.; Prassl, R. Comparative analysis of protein-protein interaction prediction tools. Life Sci., 2020, 257, 117883.
[http://dx.doi.org/10.1016/j.lfs.2020.117883] [PMID: 32497632]
[5]
Skariyachan, S.; Gopal, D.; Muddebihalkar, A.G.; Uttarkar, A.; Niranjan, V. Structural insights on the interaction potential of natural leads against major protein targets of SARS-CoV-2: Molecular modelling, docking and dynamic simulation studies. Comput. Biol. Med., 2021, 132, 104325.
[http://dx.doi.org/10.1016/j.compbiomed.2021.104325] [PMID: 33751995]
[6]
Gurung, A.B.; Ali, M.A.; Lee, J.; Farah, M.A.; Al-Anazi, K.M.; Sami, H. Biomarkers for the diagnosis and prognosis of Alzheimer’s disease: A comprehensive review. Saudi J. Biol. Sci., 2021, 28(12), 3831-3841.
[http://dx.doi.org/10.1016/j.sjbs.2021.09.042] [PMID: 34548836]
[7]
Toropov, A.A.; Toropova, A.P.; Benfenati, E. Development of a new QSAR model for predicting the potential genotoxicity of chemicals. SAR QSAR Environ. Res., 2021, 32(4), 239-250.
[http://dx.doi.org/10.1080/1062936X.2021.1952649] [PMID: 34293992]
[8]
Sepehri, B.; Kohnehpoushi, M.; Ghavami, R. High predictive QSAR models for predicting the SARS coronavirus main protease inhibition activity of ketone-based covalent inhibitors. J. Indian Chem. Soc., 2022, 19(5), 1865-1876.
[http://dx.doi.org/10.1007/s13738-021-02426-2]
[9]
Shin, Y.S.; Lee, J.Y.; Noh, S.; Kwak, Y.; Jeon, S.; Kwon, S.; Park, C.M. Discovery of novel inhibitors of STAT3 by virtual screening and biological evaluation. Bioorg. Med. Chem. Lett., 2021, 31(12), 127667.
[http://dx.doi.org/10.1016/j.bmcl.2020.127667] [PMID: 33160024]
[10]
Tropsha, A.; Gramatica, P.; Gombar, V.K. Development and validation of a quantitative structure-activity relationship model for the prediction of mutagenicity of heterocyclic amines. QSAR Comb. Sci., 2003, 22(1), 69-77.
[http://dx.doi.org/10.1002/qsar.200390007]
[11]
Golbraikh, A.; Tropsha, A. Prediction of protein-ligand binding affinity with a combined molecular docking and molecular dynamics approach. J. Mol. Graph. Model., 2002, 20(3), 269-276.
[http://dx.doi.org/10.1016/S1093-3263(01)00123-1] [PMID: 11858635]
[12]
Supuran, C.T.; Innocenti, A.; Mastrolorenzo, A.; Scozzafava, A. Carbonic anhydrase inhibitors. Mini Rev. Med. Chem., 2004, 4(3), 189-200.
[http://dx.doi.org/10.2174/1389557043487402] [PMID: 15279596]
[13]
Pradhan, S.; Prasad, R.; Sinha, C.; Sen, P. Insights into molecular mechanisms and molecular docking studies of the binding of small molecular inhibitors to ACE2, the key receptor for SARS-CoV-2. J. Biomol. Struct. Dyn., 2021, 2021, 1-14.
[http://dx.doi.org/10.1080/07391102.2021.189704314]
[14]
Wang, J.; Zhang, Y.; Nie, W.; Luo, Y.; Deng, L. Decoding the molecular mechanism of SARS-CoV-2 infectivity by molecular dynamics simulations. Brief. Bioinform., 2021, 23(1), bbab484.
[http://dx.doi.org/10.1093/bib/bbab484] [PMID: 34850817]
[15]
Mando, H.; Hassan, A.; Gharaghani, S. Novel and predictive QSAR Model for steroidal and nonsteroidal 5α- Reductase Type II inhibitors. Curr. Drug Discov. Technol., 2021, 18(2), 317-332.
[http://dx.doi.org/10.2174/1570163817666200324170457] [PMID: 32208118]
[16]
Moussa, N.; Hassan, A.; Gharaghani, S. Pharmacophore model, docking, QSAR, and molecular dynamics simulation studies of substituted cyclic imides and herbal medicines as COX-2 inhibitors. Heliyon, 2021, 7(4), e06605.
[http://dx.doi.org/10.1016/j.heliyon.2021.e06605] [PMID: 33889764]
[17]
Tropsha, A.; Golbraikh, A. Predictive QSAR modeling workflow, model applicability domains, and virtual screening. Curr. Pharm. Des., 2007, 13(34), 3494-3504.
[http://dx.doi.org/10.2174/138161207782794257] [PMID: 18220786]
[18]
Konovalov, D.A.; Llewellyn, L.E.; Heyden, Y.V.; Coomans, D. Comparison of molecular docking results obtained using different scoring functions. J. Chem. Inf. Model., 2008, 48(12), 2081-2094.
[http://dx.doi.org/10.1021/ci800209k] [PMID: 18826208]
[19]
Roy, P.P.; Roy, K. On some aspects of variable selection for partial least squares regression models. QSAR Comb. Sci., 2008, 27(3), 302-313.
[http://dx.doi.org/10.1002/qsar.200710043]
[20]
Dimitrov, S.; Dimitrova, G.; Pavlov, T.; Dimitrova, N.; Patlewicz, G.; Niemela, J.; Mekenyan, O. A stepwise approach for defining the applicability domain of SAR and QSAR models. J. Chem. Inf. Model., 2005, 45(4), 839-849.
[http://dx.doi.org/10.1021/ci0500381] [PMID: 16045276]
[21]
Nikolova-Jeliazkova, N.; Jaworska, J. An approach to determining applicability domains for QSAR group contribution models: An analysis of SRC KOWWIN. Altern. Lab. Anim., 2005, 33(5), 461-470.
[http://dx.doi.org/10.1177/026119290503300510]
[22]
Kumar, V.; Roy, K. Development of a simple, interpretable and easily transferable QSAR model for quick screening antiviral databases in search of novel 3C-like protease (3CLpro) enzyme inhibitors against SARS-CoV diseases. SAR QSAR Environ. Res., 2020, 31(7), 511-526.
[http://dx.doi.org/10.1080/1062936X.2020.1776388] [PMID: 32543892]
[23]
Adasme, M.F.; Linnemann, K.L.; Bolz, S.N.; Kaiser, F.; Salentin, S.; Haupt, V.J.; Schroeder, M. PLIP 2021: Expanding the scope of the protein–ligand interaction profiler to DNA and RNA. Nucleic Acids Res., 2021, 49(W1), W530-W534.
[http://dx.doi.org/10.1093/nar/gkab294] [PMID: 33950214]
[24]
Todeschini, R. Chemometrics and QSPR Group. 2000.Available From, https://www.disat.unimib.it/vhml
[25]
Kiralj, R.; Ferreira, M.M.C. Basic validation procedures for regression models in QSAR and QSPR studies: Theory and application. J. Braz. Chem. Soc., 2009, 20(4), 770-787.
[http://dx.doi.org/10.1590/S0103-50532009000400021]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy